Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kardiologia polska 2018-01, Vol.76 (3), p.670-670
Hauptverfasser:	Szymański, Filip M, Płatek, Anna E, Dziadziuszko, Rafał, Łęgosz, Paweł, Palczewski, Piotr
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Afatinib Aniline Compounds Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - secondary Cardiotonic Agents - therapeutic use Cardiovascular Diseases - chemically induced Cardiovascular Diseases - prevention & control Gefitinib Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Middle Aged Nebivolol - therapeutic use Piperazines - adverse effects Piperazines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Ramipril - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!